Publikationen in Zusammenarbeit mit Forschern von Institute Catalá Oncología (26)

2024

  1. A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma

    Journal of Neuro-Oncology, Vol. 166, Núm. 3, pp. 407-415

  2. Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma (Journal of Neuro-Oncology, (2024), 166, 3, (407-415), 10.1007/s11060-023-04513-1)

    Journal of Neuro-Oncology

2023

  1. What do patients and oncologists think about the evaluation and management of cancer-related anorexia-cachexia? The Quasar_SEOM study

    Clinical and Translational Oncology, Vol. 25, Núm. 12, pp. 3479-3491

2022

  1. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores

    Journal of the National Cancer Institute, Vol. 114, Núm. 1, pp. 109-122

  2. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

    Communications biology, Vol. 5, Núm. 1, pp. 1061

  3. Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial

    Thrombosis and haemostasis, Vol. 122, Núm. 10, pp. 1653-1661

  4. Erratum: Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (European journal of human genetics : EJHG (2022) 30 3 (349-362))

    European journal of human genetics : EJHG

  5. Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy

    Frontiers in Oncology, Vol. 12

  6. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

    European journal of human genetics : EJHG, Vol. 30, Núm. 3, pp. 349-362

2020

  1. A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)

    Neuro-oncology, Vol. 22, Núm. 12, pp. 1851-1861

2018

  1. Correction to: SEOM clinical guidelines for anaplastic gliomas (2017) (Clinical and Translational Oncology, (2018), 20, 1, (16-21), 10.1007/s12094-017-1762-7)

    Clinical and Translational Oncology

  2. SEOM clinical guidelines for anaplastic gliomas (2017)

    Clinical and Translational Oncology, Vol. 20, Núm. 1, pp. 16-21

2017

  1. Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification

    Neuro-Oncology, Vol. 19, Núm. 11, pp. 1522-1531

2016

  1. Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma

    Anti-Cancer Drugs, Vol. 27, Núm. 2, pp. 133-137

2015

  1. A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma

    Clinical and Translational Oncology, Vol. 17, Núm. 9, pp. 743-750

  2. Candidate genetic modifiers for breast and ovarian cancer risk inBRCA1andBRCA2 mutation carriers

    Cancer Epidemiology Biomarkers and Prevention, Vol. 24, Núm. 1, pp. 308-316

  3. Mammographic density and breast cancer in women from high risk families

    Breast Cancer Research, Vol. 17, Núm. 1

2014

  1. Erratum: Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry [J Neurooncol, 116, (2014), 413-419, DOI 10.1007/s11060-013-1316-y]

    Journal of Neuro-Oncology

  2. Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers

    Breast Cancer Research and Treatment, Vol. 148, Núm. 2, pp. 415-421

2012

  1. Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO)

    Anti-Cancer Drugs, Vol. 23, Núm. 6, pp. 659-665